Bio-Pharm Solutions Co. Ltd.
Drug developer focused on central nervous system (CNS) disorders and rare diseases. Operates discovery, preclinical and clinical development for small-molecule therapeutics, pursues regulatory filings with major agencies (US FDA, Korea MFDS, EMA), and engages in technology licensing and global collaborations.
Industries
Nr. of Employees
small (1-50)
Bio-Pharm Solutions Co. Ltd.
Patents
Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
US-11931332-B2
View DetailsSulfamate derivative compounds for use in treating or alleviating a psychiatric disorder
US-11896593-B2
View DetailsCarbamate derivative compounds, processes for preparing them and their uses
US-11168052-B2
View DetailsPhenyl carbamate compound and a composition for neuroprotection comprising the same
US-10525030-B2
View DetailsSulfamate derivative compounds, processes for preparing them and their uses
US-10351519-B2
View Details
Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
US-11931332-B2
View DetailsSulfamate derivative compounds for use in treating or alleviating a psychiatric disorder
US-11896593-B2
View DetailsCarbamate derivative compounds, processes for preparing them and their uses
US-11168052-B2
View DetailsPhenyl carbamate compound and a composition for neuroprotection comprising the same
US-10525030-B2
View DetailsSulfamate derivative compounds, processes for preparing them and their uses
US-10351519-B2
View DetailsProducts
Clinical‑stage small‑molecule candidate for epilepsy and related indications
Lead clinical‑stage small‑molecule candidate developed for infantile spasms, status epilepticus and other seizure disorders; progressed through IND submissions and clinical studies.
Clinical‑candidate for neuropathic pain (early clinical stage)
Small‑molecule candidate developed for diabetic neuropathic pain with Phase I IND activity and regulatory approval to initiate first-in-human studies.
Discovery and preclinical portfolio for additional CNS and pain indications
Multiple discovery and preclinical small‑molecule programs targeting indications such as Alzheimer’s disease, Parkinson’s disease, LGS/Dravet syndromes, neuropathic and cancer pain.
ADD422007
A new drug candidate focused on the treatment of diabetic neuropathic pain.
ADD485002
A new drug candidate focused on Parkinson's disease therapeutics.
JBPOS0101
A leading pipeline candidate drug developed by Bio-Pharm Solutions for the management of pain, infantile spasms, Lennox-Gastaut syndrome, Alzheimer's disease, complex regional pain syndrome, status epilepticus, refractory status epilepticus, and Dravet syndrome.
Clinical‑stage small‑molecule candidate for epilepsy and related indications
Lead clinical‑stage small‑molecule candidate developed for infantile spasms, status epilepticus and other seizure disorders; progressed through IND submissions and clinical studies.
Clinical‑candidate for neuropathic pain (early clinical stage)
Small‑molecule candidate developed for diabetic neuropathic pain with Phase I IND activity and regulatory approval to initiate first-in-human studies.
Discovery and preclinical portfolio for additional CNS and pain indications
Multiple discovery and preclinical small‑molecule programs targeting indications such as Alzheimer’s disease, Parkinson’s disease, LGS/Dravet syndromes, neuropathic and cancer pain.
ADD422007
A new drug candidate focused on the treatment of diabetic neuropathic pain.
ADD485002
A new drug candidate focused on Parkinson's disease therapeutics.
JBPOS0101
A leading pipeline candidate drug developed by Bio-Pharm Solutions for the management of pain, infantile spasms, Lennox-Gastaut syndrome, Alzheimer's disease, complex regional pain syndrome, status epilepticus, refractory status epilepticus, and Dravet syndrome.
Services
Protocol design and operational management for Phase I and Phase II clinical trials and PK/PD studies across US and Korea regulatory frameworks.
Collaborative in‑vivo/in‑vitro pharmacology, translational assay systems and ADME study support in partnership with external experts and research institutes.
Licensing of development and commercialization rights for pipeline candidates and negotiation of territory‑specific deals.
Protocol design and operational management for Phase I and Phase II clinical trials and PK/PD studies across US and Korea regulatory frameworks.
Collaborative in‑vivo/in‑vitro pharmacology, translational assay systems and ADME study support in partnership with external experts and research institutes.
Licensing of development and commercialization rights for pipeline candidates and negotiation of territory‑specific deals.
Expertise Areas
- CNS drug development
- Rare disease therapeutics
- Preclinical pharmacology and translational research
- Clinical trial design and execution (Phase I/II, PK/PD)
Key Technologies
- New chemical entity design
- Small-molecule synthesis and process development
- In‑vivo phenotyping and translational assays
- Preclinical CNS animal models
News & Updates
Announcement of a license agreement transferring development rights for a candidate compound for infantile spasms and partial‑onset seizures to a China-based partner (November 2021).
Announcement of completion of a pre-IPO funding round reported as 750억 KRW with participation from multiple financial investors (reported August 2022).
Company reports regulatory approval to initiate a Phase I clinical trial for a neuropathic pain small‑molecule candidate (reported August 2022).
Company reports completion of Phase 2a studies for a pediatric and adult epilepsy candidate and ongoing Phase 2a activity for status epilepticus (reported August 2022).
Obtained US FDA investigational new drug (IND) authorization for a first epilepsy candidate (2013).
Received regulatory orphan drug and rare pediatric disease designations for pediatric epilepsy indications.
Announcement of a license agreement transferring development rights for a candidate compound for infantile spasms and partial‑onset seizures to a China-based partner (November 2021).
Announcement of completion of a pre-IPO funding round reported as 750억 KRW with participation from multiple financial investors (reported August 2022).
Company reports regulatory approval to initiate a Phase I clinical trial for a neuropathic pain small‑molecule candidate (reported August 2022).
Company reports completion of Phase 2a studies for a pediatric and adult epilepsy candidate and ongoing Phase 2a activity for status epilepticus (reported August 2022).
Obtained US FDA investigational new drug (IND) authorization for a first epilepsy candidate (2013).
Received regulatory orphan drug and rare pediatric disease designations for pediatric epilepsy indications.